DBCO-PEG4-Val-Cit-PAB-MMAF CAS:2244602-23-9 is a sophisticated drug-linker molecule, comprising a dibenzocyclooctyne (DBCO) group, a cleavable 4-unit polyethylene glycol (PEG4) linker, a valine-citrulline (Val-Cit) dipeptide, a para-aminobenzyl (PAB) carbamate, and the potent tubulin polymerization inhibitor monomethyl auristatin F (MMAF). This complex enables efficient synthesis of next-generation antibody-drug conjugates (ADCs).
Introduction to the application:
In pharmaceutical research and development, DBCO-PEG4-Val-Cit-PAB-MMAF plays a crucial role in designing ADCs for targeted cancer therapy. The innovative drug-linker complex allows for precise delivery of the powerful MMAF cytotoxic agent to cancer cells, minimizing off-target effects and improving treatment efficacy. The cleavable PEG4-Val-Cit-PAB linker ensures stability in the bloodstream and selective release within tumor cells, contributing to the development of safer and more effective anticancer therapeutics.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.